Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioIBD: Biomarkers for Biologics and Tofacitinib in IBD
NCT03885713Phase 4Completed
- Sponsor
- Fundación de Investigación Biomédica del Hospital Universitario de La Princesa
- Start
- Sep 2019
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 4, open-label trial of infliximab, adalimumab, golimumab, vedolizumab, ustekinumab and 1 more in Crohn's disease and ulcerative colitis (UC) (2 arms), sponsored by Fundación de Investigación Biomédica del Hospital Universitario de La Princesa. Primary endpoint: Predictive tissue and blood biomarkers for response at 14 weeks. Started Sep 2019; status: completed.
02
Drugs
03
Conditions
Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03885713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03885713.